Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

49.78 -9.37 (-15.84%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
HIMS Q2 Deep Dive: International Expansion and Product Shifts Define Next Growth Phase
Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects... 
Via StockStory
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the disclosure of significant stock sales by top executives, including CEO Andrew Dudum. According... 
Via StockStory
Topics Artificial Intelligence Lawsuit Regulatory Compliance
Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases. 
Via Benzinga
Topics Lawsuit
Where Will Hims & Hers Be in 5 Years?
Could this be the telehealth breakout Wall Street is underestimating? 
Via The Motley Fool
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
The stock remains very volatile. 
Via The Motley Fool
MarketBeat Week in Review – 08/04 - 08/08
Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales 
Via MarketBeat
Topics ETFs Economy World Trade
Why Hims & Hers Stock Sank This Week
The telehealth platform is growing quickly but is in the middle of a legal battle. 
Via The Motley Fool
Topics Lawsuit
Capital Compounders for Investors
From overvalued stocks to outsize returns, some capital compounders keep breaking the mold. 
Via The Motley Fool
Should You Buy Hims & Hers Stock on the Dip?
The healthcare company is experiencing excellent sales growth, but investors are concerned about its longer-term prospects. 
Via The Motley Fool
Hims & Hers: A Game-Changer in Telehealth or Just Another Fad?
Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks involved in this insightful analysis. 
Via The Motley Fool
2 Surging Stocks to Research Further and 1 We Turn Down
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy
The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk. 
Via Investor's Business Daily
Topics Earnings
Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to Buy
Hims & Hers falls into a buying opportunity followng the Q2 release and guidance update but investors shouldn't rush to get in, wait for this market to bottom. 
Via MarketBeat
These Are the Smartest Growth Stocks to Invest $1,000 in Today
These growth stocks come from completely different industries, but each has something to offer long-term investors. 
Via The Motley Fool
Novo Nordisk Edges Up Premarket As Q2 Wegovy Sales Defy Copycat Threats: Retail Stays Bullish Amid Tariff Pressure
The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance. 
Via Stocktwits
Topics Government World Trade
Market Monitor News August 06 BMO - Wall Street Slides as Services Sector Falters, but Palantir Rockets Past Expectations
A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red. 
Via Chartmill
Topics Economy
Stock Market Today: Hims & Hers Tumbles 12% on Revenue Miss Despite 73% Growth
Hims & Hers stock fell sharply Tuesday after the company missed Q2 revenue estimates, despite strong growth and reaffirmed guidance. 
Via The Motley Fool
Earnings Season Wrap-Up: Tech Giants Shine, Others Face Mixed Results
The latest earnings season, spanning late July and early August 2025, has painted a vivid picture of a bifurcated market, where the titans of technology continue to defy gravity, largely propelled by... 
Via MarketMinute
Topics Artificial Intelligence Economy
US Market Under Pressure: Amazon, Eastman Chemical, and Hims & Hers Among Top Losers
The U.S. stock market experienced a turbulent start to August 2025, marked by significant declines for several prominent companies. This downturn, following a volatile end to July, has left investors... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Palantir, Pfizer, Hims & Hers, Intel, UnitedHealth: Stocks Making The Biggest Moves Today
Via Stocktwits
Hims & Hers Stock Is Trading Lower Tuesday: What's Going On?
 
Via Benzinga
Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say
Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, including regulatory complexity. 
Via Benzinga
Stocks Drop As Trump Tariffs Fuel Inflation, Palantir Hits $400 Billion Value: What's Moving Market Tuesday?
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc. 
Via Benzinga
Topics Economy Government
Why Hims & Hers Health Stock Just Dropped
Hims & Hers stock just got cheaper -- and it's still too expensive to buy. 
Via The Motley Fool
Why Did Hims & Hers Stock Crash and Then Recover After Earnings?
HIMS stock was down 13% after the company reported earnings. 
Via The Motley Fool
3 Stocks to Hold for 20 Years
These stocks have decades of compounding growth ahead. 
Via The Motley Fool
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (3 Ratings)
 
Via Benzinga
Novo Nordisk Stock Sinks—But Is a Bottom Finally In?
Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings 
Via MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.